COHERUS BIOSCIENCES INC. - COMMON STOCK

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

03 Jul 2024 06:46:52 By NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

02 Jul 2024 08:28:48 By NetDania Notify

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

27 Jun 2024 05:26:59 By Nasdaq GlobeNewswire

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

05 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

30 May 2024 06:00:00 By Nasdaq GlobeNewswire

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 14:51:06 By Nasdaq GlobeNewswire

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

23 May 2024 06:00:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 13:01:00 By Nasdaq GlobeNewswire

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

09 May 2024 04:30:00 By Nasdaq GlobeNewswire

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

08 May 2024 06:00:00 By Nasdaq GlobeNewswire

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

01 May 2024 13:30:00 By Nasdaq GlobeNewswire

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 07:02:18 By Nasdaq GlobeNewswire

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

08 Apr 2024 05:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

13 Mar 2024 13:01:00 By Nasdaq GlobeNewswire

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

05 Mar 2024 13:01:00 By Nasdaq GlobeNewswire

Coherus Completes Divestiture of Ophthalmology Franchise

03 Mar 2024 22:00:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

23 Feb 2024 14:33:13 By Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

21 Feb 2024 05:30:00 By Nasdaq GlobeNewswire

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

05 Feb 2024 05:00:01 By Nasdaq GlobeNewswire

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

21 Jan 2024 22:15:00 By Nasdaq GlobeNewswire